US Stock Market Move | Odyssey Therapeutics (ODTX.US) debuts on the US stock market, with minimal fluctuations in the opening stock price.
As of press time, the stock has fallen more than 1%, to $17.81.
On Friday, Odyssey Therapeutics (ODTX.US) debuted on the US stock market with an IPO price of $18. The stock opened with little fluctuation and by the time of writing, it had dropped more than 1% to $17.81. Odyssey Therapeutics is a clinical-stage biotechnology company based in Boston, focusing on the research and development of drugs for autoimmune and inflammatory diseases. The company's core product is OD-001, a small molecule drug for the treatment of ulcerative colitis, which is currently in mid-stage clinical trials. In addition, the company has pipelines for other immune diseases such as lupus and atopic dermatitis.
Related Articles
Huajin Securities: A-shares in June continue to fluctuate with a slight bias towards strength, the technology sector remains unchanged.
New Stock Outlook | Four major dividends boost performance release acceleration, can Ingenic Semiconductor (300223.SZ) go to Hong Kong for a "scarcity" price reevaluation?
Key NGS certificate terminated registration, facing a vacuum period of good news Burning Rock Biotech Ltd. Sponsored ADR Class A (BNR.US) stock price fell more than 40% on the 5th.
Huajin Securities: A-shares in June continue to fluctuate with a slight bias towards strength, the technology sector remains unchanged.
New Stock Outlook | Four major dividends boost performance release acceleration, can Ingenic Semiconductor (300223.SZ) go to Hong Kong for a "scarcity" price reevaluation?
Key NGS certificate terminated registration, facing a vacuum period of good news Burning Rock Biotech Ltd. Sponsored ADR Class A (BNR.US) stock price fell more than 40% on the 5th.
